Virginia · 2026 Regular Session · Bill

HB 712: Office-based buprenorphine treatment; Board of Medicine to amend regulations.

Enacted Last action April 6, 2026: Acts of Assembly Chapter text (CHAP0207)

Plain-language summary

HB 712 is a bill introduced in the Virginia House on January 13, 2026. According to its official title, it concerns: Office-based buprenorphine treatment; Board of Medicine to amend regulations. Primary sponsor: Otto Wachsmann (Republican). Most recent recorded action (April 6, 2026): Acts of Assembly Chapter text (CHAP0207).

Sponsors

Primary sponsor: Otto Wachsmann (Republican).